{
  "ticker": "AN1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973403",
  "id": "02973403",
  "pages": 7,
  "price_sensitive": true,
  "date": "20250728",
  "time": "1623",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6xh48s6m355.pdf",
  "summary": "### **Anagenics Limited \u2013 Quarterly Report (Appendix 4C) \u2013 Key Highlights**  \n\n- **Operating Cash Flow**: Positive **$132k** for the quarter (vs. negative **$1.576m** year-to-date).  \n- **Cash Balance**: **$395k** at quarter-end.  \n- **Flouf Factor Growth Tonic**: On track to exceed **$9m** in first-year sales, ahead of expectations. Potential international expansion under evaluation.  \n- **Roquefort Therapeutics Licensing**: Discussions ongoing; deadline extended to **31 August 2025**. No material update.  \n- **Funding Sufficiency**: Sufficient liquidity for **next two quarters** without requiring equity raising.  \n- **Debt Facilities**:  \n  - **Unsecured loans**: **$565k** drawn (total facility: **$790k**).  \n  - **Secured facility**: **$1.0m** (undrawn; expires March 2027).  \n  - Total available funding: **$1.62m** (cash + unused facilities).  \n\n*No other material information identified.*",
  "usage": {
    "prompt_tokens": 3988,
    "completion_tokens": 233,
    "total_tokens": 4221,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T06:50:48.563459"
}